Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Status:
Completed
Trial end date:
2020-08-13
Target enrollment:
Participant gender:
Summary
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab
govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously
treated participants with advanced epithelial cancer. In Phase II, the primary objective is
to evaluate the safety and efficacy of sacituzumab govitecan-hziy administered in 21-day
treatment cycles at a dose selected in Phase I.
Tumor types in the study will include: cervical, colorectal, endometrial, ovarian,
esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous
cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell,
small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast
cancer (TNBC) and metastatic urothelial cancer (mUC).